Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221370 · ClinicalTrials.gov registry record · Phase 2
Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients
A Phase 2 study of Clostridium Difficile Infection and Vancomycin Resistant Enterococci Infection, sponsored by Riverside University Health System Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
- 1
- Study location
NCT07221370 is a Phase 2 study of Clostridium Difficile Infection and Vancomycin Resistant Enterococci Infection that is actively recruiting participants, run by Riverside University Health System Medical Center. The registered enrollment target is 176 participants, below the 12,052-participant average among 13 other Clostridium Difficile Infection trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07221370, a Phase 2 study of Clostridium Difficile Infection and Vancomycin Resistant Enterococci Infection, is actively recruiting participants, sponsored by Riverside University Health System Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to determine if oral vancomycin can prevent C.diff infection in adults who are critically ill and are at high risk of C.diff infection due to their medical conditions and being in the hospital. It will also help us learn about the safety of the drug in this setting. The main questions the trial aims to answer are: * Does oral vancomycin lower the rate of C.diff infection in high-risk patients? * Does C.diff carrier status change the C.diff infection rate as well as clearance of carrier status when vancomycin is used as primary prophylaxis? Researchers will compare the oral, active drug vancomycin to a placebo (a look-alike substance that contains no drug) to determine if vancomycin works to prevent C.diff infection in the hospital. Participants will: * Take oral vancomycin or a placebo while they receive systemic antibiotic(s) for up to five days after the last dose of said systemic antibiotic(s). The treatment of said systemic antibiotic(s) is not to exceed 21 days. * When discharged from the hospital, participants will continue to take the study medication in the event he/she did not complete the intended course of the study medication while in the hospital. * Participants will provide stool sample or rectal swabs for to assess their C.diff carrier status as well as any change in stool microbiome status, including VRE (vancomycin resistant Enterococcus) * After completion of the intervention period, participants will be contacted via telephone to assess if they developed diarrhea or any untoward effects of study medication.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Vancomycin 125mg
Study Locations (1)
California
- Riverside University Health System - Moreno Valley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2024-10-21 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07221370
The ClinicalTrials.gov registry entry for NCT07221370 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,052-participant average among 13 other Clostridium Difficile Infection trials with a reported enrollment target (99% lower). The listed sponsor is Riverside University Health System Medical Center, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Clostridium Difficile Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07221370 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07221370 about?
NCT07221370 is a clinical study titled "Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients". The goal of this clinical trial is to determine if oral vancomycin can prevent C.diff infection in adults who are critically ill and are at high risk of C.diff infection due to their medical conditions and being in the hospital. It will also help us learn about the safety of the drug in this setting...
What is the current status of trial NCT07221370?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2024-10-21. Estimated completion is 2026-12-31.
What conditions does trial NCT07221370 study?
This clinical trial studies the following conditions: Clostridium Difficile Infection, Vancomycin Resistant Enterococci Infection.
What interventions are being tested in trial NCT07221370?
The interventions under investigation include: Placebo (DRUG), Vancomycin 125mg (DRUG).
Who is sponsoring clinical trial NCT07221370?
This trial is sponsored by Riverside University Health System Medical Center, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07221370 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clostridium Difficile Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
RECRUITING · Phase 2
-
The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation
COMPLETED · Phase 2
-
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
COMPLETED · Phase 2
-
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
COMPLETED · Phase 2
-
Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)
COMPLETED · Phase 2
-
Study of CB-183,315 in Participants With Clostridium Difficile Infection
COMPLETED · Phase 2
Explore more on PlainTrial
Clostridium Difficile Infection
All registered trials for this condition
Vancomycin Resistant Enterococci Infection
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.